

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 2

PATENT
Attorney Docket No. SALK1520-2

OFFICIAL

In The Claims:

Please cancel claim 25 to 34 and 43 to 46 without prejudice, and amend claims 1, 11, 12 and 20 to 24 as follows:

1. (Amended) A method for modulating the expression of an exogenous gene in a [mammalian subject] cell containing:

- (i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
- (ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;

said method comprising [administering to said subject] providing to the cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in the [cells of said subject] cell; and wherein said ligand is not toxic to said [subject] cell.

11. (Amended) A method according to claim [1] 47 wherein said receptor capable of acting as a silent partner is RXR.

12. (Amended) A method according to claim 11 wherein said RXR is exogenous to said mammalian [subject] cell.

20. (Amended) A method according to claim 19 wherein said wild type gene is selected from genes which encode products:

the substantial absence of which leads to the occurrence of a non-normal state in said [subject] cell; or

a substantial excess of which leads to the occurrence of a non-normal state in said [subject] cell.

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 3

PATENT
Attorney Docket No. SALK1520-2

21. (Amended) A method according to claim 19 wherein said therapeutic gene is selected from those which encode products:

which are toxic to the cells in which they are expressed; or
which impart a beneficial property to said **[subject] cells**.

22. (Amended) A method of inducing the expression of an exogenous gene in a **[mammalian subject] cell** containing:

(i) a DNA construct comprising an exogenous gene under the control of an ecdysone response element,

(ii) DNA encoding a modified ecdysone receptor under the control of an inducible promoter; wherein said modified ecdysone receptor, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element, and

(iii) a ligand for said modified ecdysone receptor;
said method comprising subjecting said **[subject] cell** to conditions suitable to induce expression of said modified ecdysone receptor.

23. (Amended) A method of inducing expression of an exogenous gene in a **[mammalian subject] cell** containing a DNA construct containing said exogenous gene under the control of an ecdysone response element, said method comprising introducing into said **[subject] cell**:

a modified ecdysone receptor, and

a ligand for said modified ecdysone receptor,

wherein said receptor, in combination with a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element, activating transcription therefrom.

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 4

PATENT
Attorney Docket No. SALK1520-2

24. (Amended) A method for the expression of a recombinant product detrimental to [a host organism] host cells, said method comprising:
transforming suitable host cells with:
(i) a DNA construct encoding said recombinant product under the control of an ecdysone response element, and
(ii) DNA encoding a modified ecdysone receptor;
growing said host cells in suitable media; and
inducing expression of said recombinant product by introducing into said host cells ligand(s) for said modified ecdysone receptor, and optionally a receptor capable of acting as a silent partner for said modified ecdysone receptor.

Please add new claims 47 to 56 as follows:

-
47. (New) A method according to claim 1, wherein said receptor capable of acting as a silent partner is present.
48. (New) A method according to claim 47 wherein said receptor capable of acting as a silent partner is ultraspiracle.
49. (New) A method according to claim 1 wherein said modified ecdysone receptor has substantially no binding affinity for endogenous response elements.
-

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 5

PATENT
Attorney Docket No. SALK1520-2

50. (New) A method for modulating the expression of an exogenous gene in a cell containing:
- (i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
 - (ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;

said method comprising providing to said cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in said cell; and wherein said ligand is not toxic to said cell.

51. (New) A method according to claim 52, wherein said receptor capable of acting as a silent partner is RXR.

52. (New) A method according to claim 52, wherein said receptor capable of acting as a silent partner is ultraspiracle.

53. (New) A method for modulating the expression of an exogenous gene in a mammalian cell containing:

- (i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
- (ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;

said method comprising providing to said mammalian cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in said mammalian cell; and wherein said ligand is not toxic to said mammalian cell.

54. (New) A method according to claim 1, wherein said receptor capable of acting as a silent partner is present.